Forskning ved Københavns Universitet - Københavns Universitet

Forside

Biologiske behandlingsmuligheder ved Graves' oftalmopati

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

The current medical treatment options for Graves' ophthalmopathy (GO) are unsatisfactory. Recent treatment of GO patients with the B-lymphocyte depleting monoclonal antibody rituximab or with the anti-tumor necrosis factor-alpha agents etanercept and infliximab has shown promising results. We discuss the use of these and other biological agents targeting B lymphocytes, T-lymphocyte interaction with antigen-presenting cells, or cytokines in the future treatment of GO.
OriginalsprogDansk
TidsskriftUgeskrift for Laeger
Vol/bind170
Udgave nummer24
Sider (fra-til)2128-30
Antal sider3
ISSN0041-5782
StatusUdgivet - 9 jun. 2008

ID: 34072671